🏆 Deal of the Week · CW 44/2024
AgomAb Therapeutics raised EUR 82.1 million in a Series D financing round, with the valuation remaining undisclosed. The round was backed by Invus and Sanofi. The capital will support the advancement of AgomAb's fibrosis-focused clinical pipeline across multiple indications.
AgomAb Therapeutics — key deal facts
| Company | AgomAb Therapeutics |
| Founded | 2017 |
| Headquarters | Antwerp, Belgium |
| Amount raised | EUR 82.1m |
| Valuation | Valuation Remains Undisclosed |
| Round | Series D |
| Investors | Invus, Sanofi |
| Sectors | Biotechnology |
Who invested in AgomAb Therapeutics?
The Series D was funded by Invus and Sanofi. The participation of Sanofi, a global pharmaceutical leader with established interests in immunology and rare diseases, alongside specialist life-sciences investor Invus, signals strong institutional conviction in AgomAb's growth-factor-targeting approach to fibrosis. This combination of strategic and financial capital is notable for a clinical-stage biotech operating in a high-barrier therapeutic area.
What does AgomAb Therapeutics do?
AgomAb Therapeutics is a clinical-stage biotechnology company founded in 2017 and headquartered in Antwerp, Belgium. The company develops disease-modifying therapies that target growth factor pathways to resolve fibrosis, repair tissue structure, and restore organ function in severe fibrotic and fibro-inflammatory conditions. Its lead programs address high-unmet-need indications including fibrostenosing Crohn's disease and other chronic fibrotic organ conditions. The company is led by Chief Executive Officer Tim Knotnerus.
AgomAb Therapeutics valuation & multiples
Explore the benchmarks: Series D.
Frequently asked questions
How much did AgomAb Therapeutics raise in its Series D?
AgomAb Therapeutics raised EUR 82.1 million in its Series D financing round, announced in October 2024.
What is AgomAb Therapeutics's valuation?
AgomAb Therapeutics's valuation was not disclosed as part of the Series D financing.
Who invested in AgomAb Therapeutics?
The Series D round was backed by Invus and Sanofi.
When was AgomAb Therapeutics founded and where is it based?
AgomAb Therapeutics was founded in 2017 and is headquartered in Antwerp, Belgium.
Source: original announcement — read the full report.